Vitamin D treats Gestational Diabetes, decreases hospitalization and newborn complications – meta-analysis March 2019

There are two gestational diabetes mellitus meta-analyses on this page

Efficacy of vitamin D supplementation in gestational diabetes mellitus: Systematic review and meta-analysis of randomized trials.

PLoS One. 2019 Mar 22;14(3):e0213006. doi: 10.1371/journal.pone.0213006. eCollection 2019.
Rodrigues MRK1, Lima SAM2, Mazeto GMFDS3, Calderon IMP1, Magalhães CG1, Ferraz GAR1, Molina AC4, Costa RAA1, Nogueira VDSN3, Rudge MVC1.

VitaminDWiki

Items in all 3 categories Diabetes AND Pregnancy AND Meta-analysis are listed here:

Items in both categories Diabetes and Pregnancy are listed here:

 Download the PDF from VitaminDWiki


BACKGROUND: Trials have examined on the benefits of vitamin D supplementation in pregnant women.

OBJECTIVE:
This review aimed to evaluate whether oral vitamin D supplements, when given to pregnant women with gestational diabetes mellitus (GDM), would improve maternal and neonatal outcomes, compared with no treatment or placebo.

METHOD:
We performed a systematic review following Cochrane methodology, and randomized trials were included where pregnant women with GDM received vitamin D supplementation versus placebo/no treatment or vitamin D and calcium versus placebo/no treatment. Primary outcomes were preeclampsia, preterm birth, cesarean delivery, gestational hypertension, and adverse events related to vitamin D supplementation. The search strategies were applied to the following databases: MEDLINE, Embase, LILACS, and CENTRAL. Similar outcomes in at least two trials were plotted using Review Manager 5.3 software. The quality of evidence was generated according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE).

RESULTS:
The total of 1224 references were identified, eleven trials were potentially eligible, and six were included in this review (totaling 456 women). The meta-analysis of frequency of cesarean deliveries did not show significant differences between groups, none of the trials evaluated the remaining primary outcomes. For secondary outcomes, our results suggest that vitamin D supplementation in pregnant women with GDM
may reduce newborn complications such as

  • Hyperbilirubinemia, RR: 0.40, 95% CI: 0.23 to 0.68;
  • Polyhydramnios RR: 0.17, 95% CI: 0.03 to 0.89;
  • maternal hospitalization (RR: 0.13; 95% CI: 0.02 to 0.98;
  • infant hospitalization RR: 0.40, 95% CI: 0.23 to 0.69.

However, the evidence was of low or very low quality.

CONCLUSION:
We did not find moderate or high quality evidence indicating that vitamin D supplementation, when compared with placebo, improves glucose metabolism, adverse maternal and neonatal outcomes related to GDM in pregnant women.


[Effect of vitamin D supplementation on gestational diabetes mellitus:a Meta-analysis] - Sept 2019

Wei Sheng Yan Jiu. 2019 Sep;48(5):811-821. [ Article in Chinese]
Yin W1, Jin D1, Yao M1, Yu W1, Zhu P1.
Department of Maternal, Child & Adolescent Health, School of Public Health, Xiangcheng District, Suzhou 230032, China.

OBJECTIVE:
This Meta-analysis of randomized controlled trial( RCT) was conducted to summarize the preventive and therapeutic effects of vitamin D supplementation on gestational diabetes mellitus( GDM).

METHODS:
The electronic database( CNKI, CBM, VIP, PubMed, Cochrane library, Web of Science) were systematically searched from inception to February 2018, using the keywords vitamin D and gestational diabetes to identify Meta-analysis.

RESULTS:
A total of 16 RCTs were included. A total of 6 RCTs were included for the prevention of GDM by vitamin D supplementation. Meta-analysis indicated that vitamin D supplementation significantly reduced the level of fasting plasma glucose( FPG)( SMD =-1. 87, 95% CI-3. 39- 0. 35) and the incidence of GDM( OR = 0. 42, 95% CI 0. 30-0. 60) in pregnant women. Ten RCTs were included for the treatment of GDM by vitamin D supplementation. Meta-analysis indicated that vitamin D supplementation significantly reduced the level of fasting plasma glucose( FPG)( SMD =-0. 29, 95% CI-0. 56- 0. 02) and Fasting Insulin( FINS)( SMD =-0. 42, 95% CI-0. 69- 0. 15), also improved the homeostasis model of assessment-estimated insulin resistance( HOMA-IR)( SMD =-0. 53, 95% CI-0. 890. 17) and the homeostasis model of assessment-estimated B cell function( HOMA-β)( SMD =-0. 39, 95% CI-0. 610. 18), and increased the quantitative insulin sensitivity check index( QUICKI)( SMD = 0. 87, 95% CI 0. 41-1. 32) in GDM patients.

CONCLUSION:
supplementation may prevent and treat GDM by an improvement in HOMA-IR, HOMA-IR and QUICKI.

1740 visitors, last modified 17 Oct, 2019,
Printer Friendly Follow this page for updates